Google (NASDAQ:GOOG): Google’s Enhanced Campaigns initiative is causing the company’s overall cost per clicks to increase according to Topeka, which keeps a $999 price target and Buy rating on the stock.
Biogen (NASDAQ:BIIB): Wells Fargo said this week’s total prescriptions for Biogen’s multiple sclerosis drug Tecfidera came in at 3,115, or up 9 percent week-over-week. Although new patient starts slowed week-over-week, the firm points out that the drug’s sales are still taking well above consensus. Wells has a Market Perform rating on the shares.
Triumph Group (NYSE:TGI): Cowen believes that Triumph Group’s new business potential is stronger than anticipated, following Embraer’s launch of its E2 jet and commitments at the Paris air show. The firm believes the E2 could become a top program for Triumph, and should outweigh the risks of a drop off in other mature programs. The firm has upgraded Triumph shares from Neutral to Outperform.
The Gap (NYSE:GPS): Topeka has raised its price target to $50 from $45 on shares of Gap, as the firm thinks that the company’s key brands are just beginning to recapture years of lost market share.The firm expects the company’s sales and earnings to continue to improve, and it reiterates a Buy rating on the stock.
Don’t Miss: France Has a Problem With Amazon’s Discounts.